(Finance) – TP ICAP Midcap confirmed the target price (75 euros per share) and the judgment (Buy) on PharmaNutraa company listed on Euronext STAR Milan and active in the sector of mineral supplements and medical devices for muscles and joints.
“Despite the company continuing to deliver excellent publications in a challenging macroeconomic environment and the announcement of a very ambitious roadmap to 2030, the share price has fallen more than 10% since the beginning of the year – write the analysts – While multiples in the sector have always been challenging, we believe this is a interesting entry point given the quality of the group’s fundamentals and its prospects“.